Qlaris Bio is a clinical-stage biotechnology company dedicated to developing innovative, first-in-class therapies for serious and debilitating ophthalmic diseases. Founded with a mission to preserve vision and prevent blindness, Qlaris Bio focuses on addressing high unmet needs in the field of ophthalmology. The company leverages novel mechanisms of action to create impactful treatments that aim to make a significant difference in patients' lives.
Qlaris Bio has attracted notable investors and industry experts who support its groundbreaking work in eye health. The company has achieved key milestones in its clinical development programs, advancing its therapies through critical stages of research and trials. Through its relentless commitment to innovation and patient care, Qlaris Bio is making substantial contributions to the field of ophthalmology, aiming to transform the treatment landscape for debilitating eye conditions.
